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number and dosage of antihypertensive medications in either group. This
study should be regarded as hypothesis-seeking, and does not definitively
establish a difference in blood pressure response after carotid endarterec-
tomy versus carotid stenting.
Cholesterol reduction with atorvastatin improves walking distance in
patients with peripheral arterial disease
Mohler ER, Hiatt WR, Creager MA, and Study Investigators. Circulation
2003;108:1481-6.
Conclusion: Atorvastatin improves pain-free walking distance as mea-
sured with treadmill testing in patients with intermittent claudication.
Summary: This was a randomized, double-blind, parallel-design study
of 354 patients with intermittent claudication secondary to peripheral
arterial disease. Patients were given either placebo, or 10 or 80 mg/d of
atorvastatin for 12 months, and evaluated in terms of treadmill exercise time,
ankle brachial index, self-reported measures of physical activity, and quality-
of-life questionnaires.
Atorvastatin did not change maximal treadmill walking time after 12
months of treatment. Pain-free walking time was improved with the 80-mg
dose of atorvastatin (P  .025) compared with placebo. There were no
differences in ankle-brachial index between the three groups at 12 months.
Twelve vascular events occurred during follow-up: 9 in the placebo group, 1
in the 10-mg atorvastatin group, and 2 in the 80-mg atorvastatin group.
Vascular events were higher in the placebo group than in the combined
Atorvastatin groups (P  0.003). Both the 80-mg and 10-mg atorvastatin
groups demonstrated improved physical activity compared with the placebo
group. There were no differences in quality of life as measured by the
short-form health survey (36 items) and Walking Impairment Question-
naire.
Comment: The heart protection study (Lancet 2002;360:7-22) dem-
onstrated a reduction in risk for death and adverse cardiac events in patients
with peripheral arterial disease without a previous cardiovascular event who
were treated with simvastatin. The current study also indicates that a statin,
atorvastatin, can improve pain-free walking distance and physical activity in
patients with intermittent claudication. Regardless of cholesterol level, it is
highly likely that all patients with symptomatic or asymptomatic atheroscle-
rosis will benefit from a statin medication.
Regional angiogenesis with vascular endothelial growth factor in pe-
ripheral arterial disease: A phase II randomized, double-blind, con-
trolled study of adenoviral delivery of vascular endothelial growth
factor 121 in patients with disabling intermittent claudication
Rajagopalan S, Mohler ER, Lederman RJ, et al. Circulation 2003;108:
1933-8.
Conclusion: A single set of intramuscular injections of adenoviral
vascular endothelial growth factor 121 (adVEGF121) did not result in
exercise improvement, increased ankle-brachial index, or improved quality
of life in patients with intermittent claudication.
Summary: Growth of new blood vessels to improve symptomatic
ischemia is termed therapeutic angiogenesis. This trial, the Regional Angio-
genesis with Vascular Endothelial Growth Factor (RAVE) trial was the first
major randomized study to evaluate the safety and efficacy of adVEGF121
gene transfer in treatment of peripheral vascular disease.
A replication-deficient adenovirus encoding the 121 amino acid iso-
form of VEGF was injected into the lower extremities of subjects with
unilateral peripheral arterial disease. The 105 patients were stratified on the
basis of diabetic status. All had unilateral exercise-limiting intermittent
claudication, and were randomized to either high-dose or low-dose ad-
VEGF121 therapy or placebo. Drug was given as 20 intramuscular injections
in the ipsilateral leg in a single session.
At 12 weeks there were no differences in change in peak walking time
among the placebo, low-dose, and high-dose groups. In addition, secondary
end points of ankle-brachial index, claudication onset time, and quality-of-
life assessment (short-form health survey [36 items] and Walking Impair-
ment Questionnaire) did not differ among the groups at 12 and 26 weeks.
No major safety issues were identified through 1 year of follow-up.
Comment: Several possible impairments to adenoviral transfection of
adult skeletal muscle may have contributed to the negative results of this
study. Possible impairments to transfection include muscle fascia, connective
tissue, and lower concentrations in skeletal muscle of the Coxsackie adeno-
viral receptor. Angiogenesis for treatment of peripheral arterial disease is still
more an interesting idea than practical reality.
Secondary prevention of venous thromboembolism with the oral direct
thrombin inhibitor Ximelagatran
Schulman S, Wahlander K, Lundstrom T, et al. N Engl J Med 2003;349:
1712-21.
Conclusion: Ximelagatran, an oral direct thrombin inhibitor, is supe-
rior to placebo in preventing recurrent venous thromboembolism, with no
increase in bleeding complications.
Summary: In a multicenter, double-blind trial, 1233 patients with
venous thromboembolism who had undergone 6 months of standard oral
anticoagulant therapy were randomly assigned to an additional 18 months of
treatment with either placebo or 24 mg twice daily of Ximelagatran. The
primary end point was recurrent venous thromboembolism. The two groups
were compared with respect to recurrent venous thromboembolism events
and hemorrhagic complications.
Of the 612 patients assigned to the Ximelagatran group, a primary end
point was reached in 12 patients. In the 611 patients assigned to the placebo
group, a primary end point was reached in 71 patients (hazard ratio, 0.16;
95% confidence interval, 0.09-0.30; P  .001).
There were six deaths in the Ximelagatran group, and seven deaths in
the placebo group. Bleeding occurred in 134 patients given Ximelagatran,
and in 111 control patients (hazard ratio, 1.19; 95% confidence interval,
0.93-1.53; P  .17). Major hemorrhage was infrequent, occurring in 6
patients in the Ximelagatran group and 5 patients in the placebo group.
There were three fatal pulmonary emboli in the placebo group, com-
pared with none in the Ximelagatran group. There was a cumulative risk for
transient elevation of alanine aminotransferase concentration to more than
three times normal in 6.4% of the Ximelagatran group and 1.2% of the
placebo group (P .001). Increase in aminotransferase levels was transient,
restricted to the first 4 months of therapy, and did not result in progressive
hepatic dysfunction. Levels decreased spontaneously whether or not Ximel-
agatran was continued.
Comment: Ximelagatran, unlike warfarin sodium, does not have any
clinically important known food or drug interactions. This drug, with an
overall safety profile comparable to that with placebo and no need for
laboratory monitoring, appears to be a low-risk, effective method for pre-
venting recurrent venous thromboembolism. Rat poison may once again be
relegated to rats.
Risk factors for death or stroke after carotid endarterectomy: Obser-
vations from the Ontario Carotid Endarterectomy Registry
Tu JV, Wang H, Bowyer B, et al, and participants in the Ontario Carotid
Endarterectomy Registry Stroke 2003;34:2568-75.
Conclusion: A history of transient ischemic attack or stroke, contralat-
eral occlusion, diabetes, atrial fibrillation, and congestive heart failure are
independent predictors for increased risk for stroke or death at 30 days after
carotid endarterectomy.
Summary: The study used data derived from the Ontario Carotid
Endarterectomy Registry, which contains information on all carotid endar-
terectomy procedures performed in Ontario, Canada, in calendar years 1994
to 1997. Medical records of all 6038 patients undergoing carotid endarter-
ectomy during this period were abstracted for patient characteristics and
30-day perioperative stroke and death. Data from 34 hospitals and 102
surgeons are represented in the study.
Overall 30-day stroke and death rate was 6.0%. Independent predictors
of 30-day stroke or death included history of transient ischemic attack or
stroke (odds ratio [OR], 1.75; 95% confidence interval [CI], 1.39-2.20),
contralateral carotid occlusion (OR, 1.72; 95% CI, 1.25-2.38), atrial fibril-
lation (OR, 1.89; 95% CI, 1.29-2.76), congestive heart failure (OR, 1.80;
95% CI, 1.15-2.81), and diabetes (OR, 1.28; 95% CI, 1.01-1.63). Assigning
1 point to each independent predictor, a total of 4 points was associated with
a 15.8% perioperative risk for stroke or death, whereas the absence of all of
the above independent predictors predicted a 3.3% perioperative risk for
stroke or death.
Comment: This report can help determine which of the growing
number of patients said to be at “high risk” are truly at high risk for
perioperative complication after carotid endarterectomy. Like all observa-
tional studies, this study is subject to selection bias, inasmuch as no infor-
mation is provided regarding patients who were considered for carotid
endarterectomy but did not undergo the procedure.
Future studies must concentrate, not only on identifying patients who
are at high risk for carotid intervention, but also on identifying patients who
are at particularly high risk for withholding intervention.
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